Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| RAPP | CLUSTER | neutral | 3/10 | CEO Abraham Ceesay and COO Cheryl Gault sold a combined ~$368K worth of RAPP shares in open-market transactions on June | Jul 2, 2026 |
| BEAM | CLUSTER | bearish | 4/10 | CEO John M. Evans exercised options and sold shares worth ~$1.26M, while 10% owner FMR LLC sold 251,488 shares (~$8.87M) | Jul 2, 2026 |
| ZLAB | CLUSTER | neutral | 3/10 | Four Zai Lab insiders, including the CEO, CFO, and Chief Legal Officer, sold a total of ~$667K in open-market sales over | Jul 2, 2026 |
| ROIV | CLUSTER | bearish | 5/10 | Six Roivant insiders, including the President & CIO and the President & Immunovant CEO, sold a total of ~$43.3M in open- | Jul 2, 2026 |
| RVMD | CLUSTER | neutral | 2/10 | Two insiders at Revolution Medicines sold a total of $817K in stock over a 7-day window. CFO Jack Anders sold $762K (4.6 | Jul 2, 2026 |
| PCSA | CLUSTER | bullish | 5/10 | Two C-suite insiders (CFO and President of R&D) made open-market purchases totaling ~$11K on June 30, 2026, at $1.93/sha | Jul 2, 2026 |
| PGEN | CLUSTER | bearish | 5/10 | Three top executives at Precigen (CEO, CFO, COO) sold a combined $2.46M in open-market stock on June 29, 2026, with the | Jul 2, 2026 |
| IBRX | CLUSTER | neutral | 2/10 | Two directors at ImmunityBio sold a combined ~$1.06M in open-market sales over a 7-day window, with the largest sale ($8 | Jul 2, 2026 |
| MOLN | PRESS-RELEASE | neutral | 4/10 | Molecular Partners announced first patient dosing in the US Phase 1/2a study of MP0712, a DLL3-targeting 212Pb-labeled R | Jul 2, 2026 |
| TLX | PRESS-RELEASE | bullish | 7/10 | Telix announced FDA alignment to proceed to Part 2 of the ProstACT Global Phase 3 trial for TLX591-Tx in metastatic cast | Jul 1, 2026 |
| ORKA | CLUSTER | neutral | 5/10 | { "summary": "A massive insider selling cluster at Oruka Therapeutics: director/10% owner Fairmount Funds Management L | Jul 1, 2026 |
| FTH | CLUSTER | neutral | 3/10 | CEO Anand Parikh and CFO Brian Stephenson made open-market purchases totaling ~$235K over a 10-day window, following the | Jul 1, 2026 |
| CTNM | CLUSTER | neutral | 2/10 | CEO Carmine Stengone and CMO Tim Watkins sold small open-market positions on June 30, 2026, totaling $334K (0.05% of mar | Jul 1, 2026 |
| PHVS | CLUSTER | neutral | 3/10 | Three Pharvaris insiders, the Chief Medical Officer, Chief Early Development Officer, and a Director, sold a total of ~$ | Jul 1, 2026 |
| LXEO | CLUSTER | neutral | 3/10 | Two C-suite insiders (COO and CFO) at Lexeo Therapeutics sold a combined ~$42K in open-market sales on July 1, 2026, imm | Jul 1, 2026 |
| SHPH | 3 | neutral | 2/10 | HRT Financial LP filed a Form 3 initial statement of beneficial ownership with the SEC, reporting 71,842 shares of Shutt | Jul 1, 2026 |
| CMPX | 8-K | bullish | 7/10 | Compass Therapeutics furnished an updated corporate presentation disclosing positive Phase 2/3 COMPANION-002 data for to | Jul 1, 2026 |
| AXSM | 144 | neutral | 4/10 | CEO Herriot Tabuteau filed a Form 144 to sell 49,666 common shares (approx. $11.9M) under a Rule 10b5-1 plan adopted on | Jul 1, 2026 |
| CSTL | 144 | neutral | 2/10 | CEO Derek Maetzold filed a Form 144 to sell 23,844 shares (~$589K) under a pre-arranged 10b5-1 trading plan dated Decemb | Jul 1, 2026 |
| TRAW | S-3 | neutral | 5/10 | { "summary": "Traws Pharma filed a replacement S-3 shelf registration statement to carry forward $139.2M of unsold sec | Jul 1, 2026 |
| GLUE | CLUSTER | neutral | 2/10 | A cluster of 4 Monte Rosa insiders (CMO, CSO, COO, Director) sold shares totaling $467K over a week, with all sales foll | Jul 1, 2026 |
| SNDX | PRESS-RELEASE | neutral | 2/10 | Syndax granted 250,700 performance-based stock options to 8 new hires under its 2023 Inducement Plan, with four-year gra | Jul 1, 2026 |
| SGMO | 8-K | bearish | 9/10 | Sangamo Therapeutics filed an 8-K disclosing the termination of Ernst & Young as its independent auditor following its C | Jul 1, 2026 |
| JAZZ | 144 | neutral | 2/10 | Officer Bruce C. Cozadd filed a Form 144 to sell 6,000 shares of Jazz Pharmaceuticals common stock, valued at approximat | Jul 1, 2026 |
| NVCT | CLUSTER | bullish | 7/10 | CEO Ron Bentsur and 10% owner Marlio Charles Mosseri made open-market purchases totaling $1.17M on the same day as a $93 | Jul 1, 2026 |
| NVS | COURT-RULING | bearish | 5/10 | The Eighth Circuit affirmed denial of Novartis's preliminary injunction against Missouri's S.B. 751, which prohibits dru | Jul 1, 2026 |
| AZN | 6-K | neutral | 2/10 | AstraZeneca filed a routine 6-K reporting the admission of 14,784 ordinary shares issued under employee share schemes du | Jul 1, 2026 |
| AZN | 6-K | neutral | 1/10 | AstraZeneca filed a routine total voting rights notification as of 30 June 2026, confirming 1,551,024,534 ordinary share | Jul 1, 2026 |
| GSK | 6-K | neutral | 1/10 | GSK filed a routine monthly total voting rights notification under UK FCA rules, reporting 4,045,395,364 voting rights a | Jul 1, 2026 |
| HYFT | 6-K | neutral | 3/10 | MindWalk Holdings filed a European patent application (EP26187897.9) for its high-dimensional biological data architectu | Jul 1, 2026 |